Adverse reactions attributed to entire drug class 'Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)'
Please login to view adverse reactions.
Alopecia / hair loss
- (2024): Aoyama Y+, Breast Cancer 31(2), 234-242 (Chemotherapy-Induced Alopecia Distress Scale )
- (2024): Kraehenbuehl L+, Support Care Cancer 32(6), 369 (Chemotherapy-Induced Alopecia Distress Scale )
- (2022): Hrin ML+, J Am Acad Dermatol 86(6), 1434-1435 [REVIEW]
- (2018): Dunnill CJ+, Oncologist 23(1), 84-96
- (2011): Miteva M+, Am J Dermatopathol 33(4), 345-50 (10 cases)
Atrial fibrillation
Bradycardia / sinus bradycardia
Capillary leak syndrome
Cardiomyopathy
Cardiotoxicity
- (2025): Chan SHY+, Cancers (Basel) 17(2), 311 (pharmacovigilance / pharmacoepidemiology)
- (2025): Shil S+, Heart Fail Rev Jun, Online ahead of print [REVIEW]
- (2024): Jaiswal V+, Medicina (Kaunas) 60(4), 580 [REVIEW] (cardioprotective benefits associated with concomitant statin therapy)
- (2023): Qu Y+, Drug Discov Today Sep, Online ahead of print (association)
Anosmia (smell loss) / smell disorder
Dysesthesia
Dysgeusia (taste perversion)
Leukoencephalopathy / posterior reversible encephalopathy syndrome (PRES)
- (2024): Lei CL+, Expert Opin Drug Saf Mar, Online ahead of print (pharmacovigilance)
Peripheral neuropathy
- (2025): Belsky JA+, Support Care Cancer 33(4), 350 [REVIEW]

- (2025): Jiang J+, Cancer Lett Mar, Online ahead of print [REVIEW]
- (2025): Mao T+, Support Care Cancer 33(6), 514 [REVIEW]

- (2025): Yanbing L+, World J Surg Oncol 23(1), 77 [REVIEW]
- (2024): Tao Z+, Cancer Lett Dec, Online ahead of print [REVIEW]
- (2022): Tay N+, Front Mol Biosci Oct (e-Collection) [REVIEW]

- (2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (13 cases)
- (2021): Hung HW+, Int J Environ Res Public Health 18(11), 5677
- (2021): Inoue M+, Sci Rep 11(1), 11324 [REVIEW]
- (2021): Li T+, Neurol Sci 42(10), 4109-4121 [REVIEW]
- (2021): Selvy M+, Support Care Cancer 29(7), 4033-4043
- (2011): Balayssac D+, Expert Opin Drug Saf 10(3), 407-17 [REVIEW]
Gonadotoxicity
Ovarian injury /ovarian damage
Ovarian injury /ovarian damage
- (2024): Zha Y+, Zhejiang Da Xue Xue Bao Yi Xue Ban May, Online ahead of print [REVIEW]
- (2011): Hancke K+, Support Care Cancer 19(12), 1909-19 [REVIEW]
- (2001): Blumenfeld Z, J Soc Gynecol Investig 8(1 Suppl Proceedings), S60-4
- (1996): Bines J+, J Clin Oncol 14(5), 1718-29
- (1996): Blumenfeld Z+, Hum Reprod 11(8), 1620-6
Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease
- (2025): Hwang IH+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2024): Jiang T+, Ther Adv Drug Saf Jan (e-Collection) (pharmacovigilance)
- (2024): Ma Z+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW]
- (2024): Oishi K+, Respir Med, 107924
- (2023): Dai HP+, Curr Med Sci 43(1), 1-12 [REVIEW]
- (2022): Zhonghua Zhong Liu Za Zhi (Chinese) 44(7), 693-702 [REVIEW]
- (2022): Conte P+, ESMO Open 7(2), 100404
- (2022): Miyagahara T+, Asia Pac J Clin Oncol Dec, Online ahead of print6%
Pneumonitis
- (2024): Oishi K+, Respir Med Dec, Online ahead of print (interstitial lung abnormalities and other associated risk factors)
Pulmonary fibrosis
- (2024): McCall KL+, Pharmacoepidemiol Drug Saf 33(5), e5797 (association) (pharmacovigilance / pharmacoepidemiology)
Pulmonary toxicity